Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 258 • 2019 ACR/ARP Annual Meeting
Health Services Utilization as Recommended by the American Diabetes Association Among Middle-Aged Patients Disabled with Rheumatoid Arthritis and Diabetes Mellitus
Geyanne Lui¹, Mangala Rajan ¹, Lisa Kern ¹, Laura Pinheiro ¹, Monika Safford ¹, Jeffrey Curtis ² and Iris Navarro-Millan ¹, ¹Weill Cornell Medicine, New York, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Medicare beneficiaries who are disabled (coverage by the Social Security Disability Insurance (SSDI)) with rheumatoid arthritis (RA) and diabetes mellitus (DM) and under 65…
Abstract Number: 441 • 2019 ACR/ARP Annual Meeting
Multidimensional Health Assessment Questionnaire (MDHAQ) Scores in Spain vs USA: Similar Scores for Clinical Status and Self-report of Depression in Rheumatoid Arthritis (RA) but Poorer Scores for Both in Spondyloarthropathies (SpA) in Spain
Rosa Morlà¹, R. Castellanos ², Virginia Ruiz-Esquide ³, Julio Ramirez ⁴, Raimon Sanmarti ⁵, Jose Gomez-Puerta ⁵, Mariam Riad ⁶, Isabel Castrejon ⁶ and Theodore Pincus ⁶, ¹Rheumatology Unit, Xarxa Sanitaria Santa Tecla, Tarragona. Rheumatology, Fundacio Clinic, Barcelona, Barcelona, Spain, ²Fundacio Clinic. Hospital Clinic de Barcelona, Barcelona, Spain, ³Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Catalonia, Spain, ⁴Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ⁵Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain, ⁶Division of Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Associations of depression with clinical status in RA1 and differences in clinical status in different countries2 have been reported. We compared MDHAQ (multidimensional health…
Abstract Number: 466 • 2019 ACR/ARP Annual Meeting
Predicting Risk of Radiographic Progression for Patients with Rheumatoid Arthritis
Thomas Huizinga ¹, Michael Weinblatt ², Nancy Shadick ², Cecilie Heegaard Brahe ³, Mikkel Østergaard ⁴, Merete Lund Hetland ⁵, Karen Hambardzumyan ⁶, Saedis Saevarsdottir ⁶, Megan Horton ⁷, Brent Mabey ⁸, Darl Flake ⁸, Alexander Gutin ⁸, Rotem Ben-Shachar ⁷, Eric Sasso ⁹ and Jeffrey Curtis¹⁰, ¹Leiden University Medical Center, Leiden, Netherlands, ²Brigham and Women's Hospital, Boston, MA, ³EuroSpA Coordinating Center, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Glostrup, Denmark, ⁴Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, ⁵DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ⁶Karolinska Institutet, Stockholm, Sweden, ⁷Myriad Genetics, Inc., Salt Lake City, UT, ⁸Myriad Genetics, Inc, South San Francisco, CA, ⁹Crescendo Bioscience, South San Francisco, CA, ¹⁰University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The multi-biomarker disease activity (MBDA) blood test has been shown to be a predictor of risk for radiographic progression in patients with rheumatoid arthritis…
Abstract Number: 503 • 2019 ACR/ARP Annual Meeting
A Pilot Phase 1, Randomized, Double-blind, Two-arm, Parallel Group, Single-dose Study to Evaluate the Safety and Pharmacokinetics of CT-P17 and Humira in Healthy Male Subjects
Edward Keystone¹, Daniel Furst ², Malcolm Boyce ³, Frans van den Berg ³, SangJoon Lee ⁴, SungHyun Kim ⁴, YunJu Bae ⁴, GoEun Yang ⁴, JuHeon Koo ⁴, EunJin Choi ⁴ and Jonathan Kay ⁵, ¹Mount Sinai Hospital, Toronto, Canada, ²University of California, Los Angeles, CA, ³Hammersmith Medicines Research, London, United Kingdom, ⁴Celltrion Inc., Incheon, Republic of Korea, ⁵UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA
Background/Purpose: CT-P17 is a recombinant humanized monoclonal antibody that was developed as a biosimilar to the reference product, adalimumab. This was a first in human…
Abstract Number: 552 • 2019 ACR/ARP Annual Meeting
In the Real World Clinical Setting Etanercept Biosimilar SB4(BENEPAIL®) Demonstrates Equivalent Safety and Effectiveness in Biological Naïve as Well as with ENBREL® Pretreated RA,SPA, and PSA Patients
Herbert Kellner¹, ¹Praxis Prof. Herbert Kellner, Munich, Germany
Background/Purpose: Background: Biosimilar TNFα inhibitors have only become available in the last few years. Etanercept bisosimilar SB-4 Benepali® has been launched in March 2016 in…
Abstract Number: 921 • 2019 ACR/ARP Annual Meeting
Indicators of Actionable Levels of Atherosclerosis in RA Patients Who Appear to Have Low or Intermediate Atherosclerotic Cardiovascular Risk Based on Standard Risk Algorithms
Jon Giles¹, Cecilia Chung ², Mary Chester Wasko ³, Amy Kao ³, Annette Oeser ², C. Michael Stein ² and Joan Bathon ⁴, ¹Columbia University, Vagelos College of Physicians & Surgeons, New York, NY, ²Vanderbilt University, Nashville, TN, ³Allegheny Health Network-West Penn Hospital, Pittsburgh, PA, ⁴Division of Rheumatology, Columbia University, New York, NY
Background/Purpose: In the general population, statins reduces atherosclerotic cardiovascular disease (ASCVD) events in those with a computed tomography (CT)-assessed coronary artery calcium (CAC) score ≥100…
Abstract Number: 1081 • 2019 ACR/ARP Annual Meeting
Characteristics of Patients with Seropositive or Seronegative Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis: Data from the US-Based Corrona Rheumatoid Arthritis and Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registries
Alexis Ogdie¹, Mei Liu ², Sabrina Rebello ², Angel Cronin ², Blessing Dube ², Robert McLean ², Esther Yi ³, Peter Hur ³ and Philip Mease ⁴, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Corrona, LLC, Waltham, MA, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA
Background/Purpose: Rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) share many clinical features but are differentiated by key clinical and molecular characteristics. Patients…
Abstract Number: 1328 • 2019 ACR/ARP Annual Meeting
The Patient’s Perspective on a Disease Flare During Tapering of DMARDs in Rheumatoid Arthritis
Elise van Mulligen¹, Angelique Weel ², Martijn Kuijper ², Mieke Hazes* ³, Annette van der Helm-van Mil ⁴ and Pascal de Jong ¹, ¹Erasmus MC, Rotterdam, Netherlands, ²Maasstad Hospital, Rotterdam, Netherlands, ³Erasmus MC, University Medical Center Rotterdam, Department of Rheumatology, Rotterdam, The Netherlands, Rotterdam, Netherlands, ⁴LUMC, Leiden, Zuid-Holland, Netherlands
Background/Purpose: Previous studies have shown that it is possible to taper DMARDs in RA patients with an inactive disease, but this is accompanied with a…
Abstract Number: 1356 • 2019 ACR/ARP Annual Meeting
DAS28-CRP Cut-offs for High Disease Activity Assessment Is Lower Than DAS28-ESR in Rheumatoid Arthritis
Jacob Greenmyer¹, John Stacy ¹, James Beal ² and Erdal Diri ¹, ¹University of North Dakota, School of Medicine Health Sciences, Minot, ND, ²University of North Dakota, School of Medicine Health Sciences, Grandforks, ND
Background/Purpose: Rheumatoid arthritis (RA) disease activity and treatment response are usually assessed by using Disease Activity Score 28-joint count (DAS28), which can be calculated using…
Abstract Number: 1381 • 2019 ACR/ARP Annual Meeting
High Serum IgA and High Proportion of Activated Th17 and Activated Treg Cells Are Predictive Biomarkers for Remission Achievement with Abatacept in Patients with Early, Seropositive Rheumatoid Arthritis
Jun Inamo¹, Yuko Kaneko ², Jun Kikuchi ³ and Tsutomu Takeuchi ⁴, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku, Tokyo, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ⁴Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Abatacept (ABT) is a soluble fusion protein, which links cytotoxic T-lymphocyte-associated protein 4 to the modified Fc portion of IgG1. Seropositivity and a shorter…
Abstract Number: 1417 • 2019 ACR/ARP Annual Meeting
Long-Term Effectiveness and Safety of Infliximab, Golimumab and Golimumab-IV in Rheumatoid Arthritis Patients from a Prospective Observational Registry
Proton Rahman ¹, Philip Baer ², Denis Choquette ³, Wojciech Olszynski ⁴, Rafat Faraawi ⁵, Louis Bessette ⁶, Milton Baker ⁷, Raman Rai ⁵, John Kelsall ⁸, Larissa Lisnevskaia ⁹, Jodie Reis ⁴, Keltie Anderson ⁴, Emmanouil Rampakakis ¹⁰, Meagan Rachich ¹¹, Odalis Asin-Milan ¹¹, Allen Lehman ¹¹ and Francois Nantel¹¹, ¹Memorial University, Newfoundland, NL, Canada, ²Independent Rheumatology Practice, Scarborough, ON, Canada, ³Institut de Recherche en Rhumatologie de Montréal, University of Montreal, Québec, Canada., Montreal, QC, Canada, ⁴University of Saskatchewan, Saskatoon, SK, Canada, ⁵McMaster University, Hamilton, ON, Canada, ⁶Laval University, Laval, QC, Canada, ⁷Vancouver Island Health Authority, Victoria, BC, Canada, ⁸University of British Columbia, Vancouver, BC, Canada, ⁹Lakeridge Health Centre, Oshawa, ON, Canada, ¹⁰JSS Medical Research, Montreal, Canada, ¹¹Janssen Inc., Toronto, ON, Canada
Background/Purpose: Long-term registries are essential to evaluate new therapies in a patient population that differs from clinical trials and usually varies over time. The purpose was…
Abstract Number: 1775 • 2019 ACR/ARP Annual Meeting
Cholesterol Sequestering in Macrophages Contributes to the Lipid Paradox in Chronic Arthritis
Sandra Pérez-Baos¹, Junko Arakawa ², Raquel Largo ¹, Katsunori Ikewaki ² and Gabriel Herrero-Beaumont ¹, ¹IIS-Fundación Jiménez Díaz, Madrid, Madrid, Spain, ²National Defense Medical College, Tokorozawa, Saitama, Japan
Background/Purpose: Patients with active rheumatoid arthritis (RA) have increased cardiovascular mortality, paradoxically associated with reduced circulating lipid levels. Several disease-modifying antirheumatic drugs (DMARDs), such as…
Abstract Number: 1898 • 2019 ACR/ARP Annual Meeting
Rheumatoid Arthritis in Pregnancy and Offspring School Performance. a Danish Nationwide Register-Based Study
Signe Knudsen¹, Julia Simard ², Jakob Christensen ³, Thomas Lauersen ⁴, Bent Deleuran ⁵ and Bodil Bech ¹, ¹Department of Public Health, Aarhus University, Aarhus, Denmark, Aarhus, Denmark, ²Stanford University School of Medicine, Palo Alto, CA, ³Department of Neurology, Aarhus University Hospital & The National Center for Register-based Research, Aarhus University, Denmark, Aarhus, Denmark, ⁴The National Center for Register-based Research, Department of Economics and Business Economics, Business and Social Science, Aarhus University, Aarhus, Denmark, Aarhus, Denmark, ⁵Department of Biomedicine; Department of Rheumatology, Aarhus University, Aarhus, Denmark
Background/Purpose: Rheumatoid arthritis (RA) during pregnancy is a risk factor for several adverse pregnancy and child outcomes. Studies have found higher incidences of neurological and…
Abstract Number: 2053 • 2019 ACR/ARP Annual Meeting
Risk of Non-vertebral Fracture in Gout Compared to Rheumatoid Arthritis
Soo-Kyung Cho¹, Jun Liu ² and Seoyoung C. Kim ², ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ²Brigham and Women’s Hospital and Harvard Medical School, Boston
Background/Purpose: Gout is a common inflammatory arthritis, characterized by hyperuricemia leading to crystallization of uric acid in joints. Proinflammatory cytokines have been known as an…
Abstract Number: 2250 • 2019 ACR/ARP Annual Meeting
Contribution of Personality Traits, Psychological Factors and Health Related Quality of Life on Medication Adherence in Patients with RA
Kyung Min Ko¹, Su-Jin Moon ², Jung Hee Koh ¹ and Jun-Ki Min ¹, ¹Division of Rheumatology, Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, the Catholic University of Korea, Bucheon, Republic of Korea, ²Division of Rheumatology, Department of Internal Medicine, Uijeongbu St. Mary's Hospital, College of Medicine, the Catholic University of Korea, Uijeongbu, Republic of Korea
Background/Purpose: Non-adherence to long-term treatment is important in Rheumatoid arthritis (RA), as it can result in inadequate disease control and make rheumatologist to change the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].